Key result
Aldosterone receptor antagonists lower office SBP by ~10 mmHg vs control in resistant hypertension.
Why the study?
The comparative effect of different treatment regimens on resistant hypertension was evaluated using a network meta-analysis.
Do various pharmacological, device-based, and lifestyle interventions reduce blood pressure in patients with resistant hypertension?
Meta-Analysis
Do various pharmacological, device-based, and lifestyle interventions reduce blood pressure in patients with resistant hypertension?
In a network meta-analysis, MRAs and lifestyle modifications emerged as top treatments for resistant hypertension, with renal denervation serving as an effective alternative, particularly for uncontrolled diastolic blood pressure.
Answers are grounded in this paper and cite their sources.
Supports aldosterone receptor antagonists for resistant hypertension; confirms efficacy via network meta-analysis of randomized trials.
Objective: Our study tends to perform a network meta-analysis to compare the effect of different treatments on resistant hypertension (RH).Design and method: A systematic search was conducted in databases up to May 10, 2025. We conducted a network meta-analysis using random effects to compare the change of systolic/diastolic blood pressure (SBP/DBP) between the following interventions: second-generation renal denervation (RDN), aldosterone receptor antagonist (MRA), endothelin receptor antagonist, aldosterone synthase inhibitor, sodium-glucose cotransporter-2 inhibitors, baroreflex activation therapy, central arteriovenous anastomosis, lifestyle, and control group. Results: 26 eligible studies were included in the final analysis. After conducting sensitivity analyses, MRA significantly lowered both office and 24-h blood pressure (BP) compared to control group (mean difference, -10.3, [95% confidence interval, -12.74 to -8] for office SBP; -4.36, [-5.97 to -2.84] for office DBP; -9.73, [-12.18 to -7.19] for 24-h SBP; -3.22, [-5 to -1.44] for 24-h DBP). RDN effectively reduced both office and 24-h BP, and it caused a large reduction in DBP compared to control group (-6.09, [-9.04 to -3.08] for office DBP; -3.34, [-5.6 to -1.6] for 24-h DBP). Lifestyle modification effectively reduced office SBP and 24-h BP, and it as well as MRA were almost all in the top three treatments. Conclusions: MRA can be the priority treatment for RH. RDN is also a good alternative to MRA in the treatment of RH, especially in individuals characterized by uncontrolled DBP. A combination of lifestyle interventions alongside pharmacological/device-based therapies may represent the optimal approach. More trials concerning other treatments for RH are needed.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) conducted a meta-analysis in resistant hypertension. Aldosterone receptor antagonist (MRA) vs. Control group was evaluated on change of office systolic blood pressure (MD -10.3, 95% CI -12.74 to -8). Aldosterone receptor antagonists lowered office systolic blood pressure compared to control in patients with resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: